Sector News

Lilly CEO Sees Light After a Difficult Year

October 20, 2014
Life sciences
Eli Lilly & Co. is deep into what Chief Executive John C. Lechleiter calls the “toughest year” in the drug maker’s 138-year history. Revenue at Lilly has plunged because of generic competition that followed patent expirations for several of its top-selling drugs, including the antidepressant Cymbalta.
 
The 61-year-old Dr. Lechleiter, meanwhile, faced one of his own toughest years in 2013: He took a two-month medical leave to undergo and recover from surgery to repair a damaged aorta.
 
Dr. Lechleiter, who joined Lilly as a chemist in 1979 and took over as CEO in 2008, says both he and Lilly are on the mend. The company has received regulatory approval to sell three new drugs—two for diabetes and one for gastric cancer—and has more experimental drugs in late-stage clinical testing.
 
In an interview at company headquarters in Indianapolis, the CEO talked about challenges facing Lilly and the health-care industry, including his desire for corporate tax reforms, and the impact of the Affordable Care Act on pharmaceutical makers. 
 
> Read the interview on the Wall Street Journal website
 
By Peter Loftus
 

Related News

July 31, 2021

Lonza positions collagen as “key” to future of joint health market

Life sciences

NutritionInsight speaks with Lindsey Toth, associate director of product management at DFS & Ingredients, Lonza Capsules & Health Ingredients.

July 31, 2021

Novo Holdings co-leads Hemab’s US$ 55M Series A to advance next generation therapeutics for bleeding and thrombosis disorders

Life sciences

The company was created in 2020 by Novo Seeds, which worked closely with the founders to develop a commercially attractive business plan to maximise the potential of Hemab’s promising technology platform.

July 31, 2021

BD acquires Tepha to drive new innovations in soft tissue repair and regeneration

Life sciences

BD (Becton, Dickinson and Company) announced today it has acquired Tepha, Inc., a leading developer and manufacturer of a proprietary resorbable polymer technology.

Send this to a friend